PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR

Disclosed herein are a pharmaceutical composition for prevention, alleviation, or treatment of any disease selected from the group consisting of type 2 diabetes mellitus, hyperinsulinemia, impaired glucose tolerance disorder, and insulin resistance disorder, wherein the pharmaceutical composition in...

Full description

Saved in:
Bibliographic Details
Main Authors JE, In Gyu, LEE, Jung Woo, YOON, Jong Min, LEE, Don Gil, PARK, Joon Tae, AN, Kyung Mi, SONG, Haeng Jin, YOON, Hong Chul, HONG, Da Hae
Format Patent
LanguageEnglish
French
German
Published 06.03.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed herein are a pharmaceutical composition for prevention, alleviation, or treatment of any disease selected from the group consisting of type 2 diabetes mellitus, hyperinsulinemia, impaired glucose tolerance disorder, and insulin resistance disorder, wherein the pharmaceutical composition includes a GPR40 agonist and an SGLT2 inhibitor, the GPR40 agonist being a compound represented by Formula 1, a racemate of the compound, an enantiomer of the compound, a diastereomer of the compound, or a pharmaceutically acceptable salt of the compound, the racemate, the enantiomer or the diastereomer, a method of preparing the same, and a method of treating type 2 diabetes mellitus and the like using the same.
Bibliography:Application Number: EP20220796189